RAC 2.29% $1.79 race oncology ltd

General Comments / Chat, page-80

  1. 2,642 Posts.
    lightbulb Created with Sketch. 10117
    Exactly. Also what makes sense developing depends on the market prices at the time. The market for cancer drugs today is very different that it was 30 years ago. At the time bisantrene was dropped charging more than a $1000 a treatment was very hard, while today new cancer drugs can sell for more than $500,000 a treatment.

    The other major change is the field has become much more concerned about long term side effects that it was back in the 1980s. When as a doctor you don’t expect your patients to live more than a couple of years you don’t worry that they will get serious heart disease in 10 years time. As treatments for cancer have improved and patients are living much longer, delayed side effects like cardiotoxicity are much more of a concern.
 
watchlist Created with Sketch. Add RAC (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.